This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 3 of 135 for:    "familial hypercholesterolemia"

Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients

This study has been withdrawn prior to enrollment.
Information provided by:
Novartis Identifier:
First received: September 11, 2008
Last updated: September 22, 2016
Last verified: September 2016
This study will evaluate the effect of APL180 on endothelial function measured by forearm venous occlusion plethysmography in patients with familial hypercholesterolemia.

Condition Intervention Phase
Familial Hypercholesterolemia Drug: APL180 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Evaluate the Effect of APL180 on Endothelial Function in Patients With Familial Hypercholesterolemia

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change in forearm blood flow during each treatment

Enrollment: 0
Study Start Date: September 2006
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: APL180
Active Comparator: 2 Drug: APL180
Placebo Comparator: 3 Drug: Placebo


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed presence of familial hypercholesterolemia
  • Women must be sterilized or post-menopausal

Exclusion Criteria:

  • Smoking an average of greater than 10 cigarettes per day
  • History of cardiac events
  • Very low or high body weight
  • Treatment with fibrates or niacin
  • High blood triglyceride levels

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00751608

Sponsors and Collaborators
Novartis Pharmaceuticals
Principal Investigator: Novartis Novartis Investigator Site
  More Information

Responsible Party: External Affairs Identifier: NCT00751608     History of Changes
Other Study ID Numbers: CAPL180A2207
Study First Received: September 11, 2008
Last Updated: September 22, 2016

Keywords provided by Novartis:
Familial hypercholesterolemia, endothelial function, venous occlusion plethysmography, forearm blood flow, ApoAI-mimetic, endothelial dependent vasodilation

Additional relevant MeSH terms:
Hyperlipoproteinemia Type II
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hyperlipoproteinemias processed this record on September 21, 2017